This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Segatore, B.
Right arrow Articles by Amicosante, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Segatore, B.
Right arrow Articles by Amicosante, G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 1999, p. 428-431, Vol. 43, No. 2
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Italian Survey on Comparative Levofloxacin Susceptibility in 334 Clinical Isolates of Pseudomonas aeruginosa

Bernardetta Segatore,1 Domenico Setacci,1 Mariagrazia Perilli,1 Nicola Franceschini,1 Annalisa De Santis,1 Federico Marchetti,2 and Gianfranco Amicosante1,*

Department of Sciences and Biomedical Technologies, School of Medicine, University of L'Aquila, L'Aquila,1 and Hoechst Marion Roussel, Milan,2 Italy

Received 1 June 1998/Returned for modification 21 September 1998/Accepted 30 November 1998

A national survey on susceptibility patterns of 334 Pseudomonas aeruginosa isolates from intensive care units and hematology and oncology wards from 13 Italian hospitals compared the in vitro activity of levofloxacin, an injectable oral fluoroquinolone, to those of ciprofloxacin, ofloxacin, ceftazidime, imipenem, amikacin, and gentamicin. Amikacin and imipenem had the best susceptibility profiles. The activity of levofloxacin was superior to those of the other quinolones and was comparable to that of ceftazidime. The effect of levofloxacin in vitro on P. aeruginosa clinical isolates suggests that further clinical investigations are warranted.

* Corresponding author. Mailing address: Department of Sciences and Biomedical Technologies, School of Medicine, University of L'Aquila, Via Vetoio, 67010 Coppito, L'Aquila, Italy. Phone: 39 862 433455. Fax: 39 862 433433. E-mail: amicosante{at}aquila.infn.it.

Antimicrobial Agents and Chemotherapy, February 1999, p. 428-431, Vol. 43, No. 2
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Lomholt, J A, Kilian, M (2003). Ciprofloxacin susceptibility of Pseudomonas aeruginosa isolates from keratitis. Br J Ophthalmol 87: 1238-1240 [Abstract] [Full Text]  
  • Gesu, G. P., Marchetti, F., Piccoli, L., Cavallero, A. (2003). Levofloxacin and Ciprofloxacin In Vitro Activities against 4,003 Clinical Bacterial Isolates Collected in 24 Italian Laboratories. Antimicrob. Agents Chemother. 47: 816-819 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»